Approach

Summary

Licensing status

Publication and contact information

Assays & screens

Assays for resistance assessment by binding competition

Assays for resistance assessment by binding competition could be useful for identifying drug-resistant viral strains. In a proof-of-concept study, labeled Relenza zanamivir was used as a probe in competitive binding assays to identify influenza strains that were resistant to Tamiflu oseltamivir. In 137 seasonal H1N1 clinical isolates from Taiwanese patients, the binding assay showed that Tamiflu-resistant strains began to emerge in mid-2008. Next steps include developing an assay system based on the approach and running clinical validation studies.
GlaxoSmithKline plc markets Relenza to treat and prevent influenza.
Gilead Sciences Inc. and Roche market Tamiflu to treat and prevent influenza.

SciBX 5(46); doi:10.1038/scibx.2012.1214
Published online Nov. 29, 2012

Patent application filed by Academia Sinica; available for licensing

Cheng, T.-J.R. et al. Angew. Chem. Int. Ed.; published online Nov. 13, 2012;
doi:10.1002/anie.201204062
Contact: Chi-Huey Wong, Academia Sinica, Taipei, Taiwan
e-mail:
chwong@gate.sinica.edu.tw
Contact: Yih-Shyun E. Cheng, same affiliation as above
e-mail:
ysecheng@gate.sinica.edu.tw
Contact: Jim-Min Fang, National Taiwan University, Taipei, Taiwan
e-mail:
jmfang@ntu.edu.tw